Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Indolent Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Richter Transformation
• Small Lymphocytic Lymphoma

Drugs mentioned

• TG-1801
• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: CLL, SLL | Phase 1 | Status: TERMINATED